WaveTech Therapy

Millions of Americans are quietly searching for solutions that don't involve a prescription bottle, a surgeon's scalpel, or weeks of painful rehabilitation. They're living with erectile dysfunction, Peyronie's disease, chronic neuropathy, persistent sports injuries, diabetic wounds, and carpal tunnel syndrome — conditions that have historically offered limited non-pharmaceutical pathways to recovery. Wavetech Therapy was built to answer that demand directly. Founded in 2015 by a team of experienced healthcare professionals who identified a gap between patient needs and available non-invasive treatment modalities, the company pioneered a clinical franchise model centered on acoustic wave therapy, a low-intensity sound wave technology that is FDA-registered for pain reduction and increased blood flow. The science behind the treatment is substantive: sound waves stimulate tissue repair, reduce arterial plaque, rejuvenate blood vessels, and recruit stem cells to the treatment site — a biological mechanism that addresses root causes rather than masking symptoms. By June 2023, Wavetech Therapy had opened its fifth clinical location in Chattanooga, Tennessee, joining existing clinics in Greensboro, North Carolina, Raleigh, North Carolina, Knoxville, Tennessee, and Birmingham, Alabama, with additional expansion into Wilmington, North Carolina. The brand currently operates across the United States with a concentrated presence along the East Coast, and is described by its own leadership as "rapidly expanding." With Paul Janus serving as Director as of June 2023, and corporate operations anchored through WaveTech Carolinas LLC at 802 Green Valley Road, Suite 214, Greensboro, NC 27408, the brand has an identifiable operational infrastructure supporting its franchise growth. For franchise investors evaluating the intersection of healthcare services, demographic tailwinds, and non-invasive treatment demand, the Wavetech Therapy franchise opportunity occupies a distinctive niche within the broader $1.71 billion shockwave therapy market. This analysis is independent research, not promotional copy — every claim is grounded in documented data from public sources and franchise disclosure materials.

The shockwave therapy market that Wavetech Therapy competes within is one of the more compelling growth stories in healthcare services franchising today. The global shockwave therapy market was valued at approximately $1.71 billion in 2025 and is projected to reach $2.89 billion by 2031, representing a compound annual growth rate of 9.13% over that six-year period. A more device-focused analysis of the same space pegged the shock wave therapy devices market at $186.6 million in 2024, expected to grow to $296.6 million by 2034 at a CAGR of 4.6% — a figure that underscores substantial hardware investment running beneath the therapy services layer. The application breakdown reveals where the commercial opportunity concentrates: orthopedics and sports injuries commanded 46.80% of the shockwave therapy market share in 2025, while cardiology applications are projected to grow at an aggressive 12.95% CAGR through 2031. From a care-setting perspective, hospitals held 42.10% of the market in 2025, but the most important trend for franchise investors is the home-care segment, which is projected to grow at a 14.35% CAGR — the highest of any end-user category — driven by FDA-cleared portable devices and growing patient self-administration. North America captured 35.30% of total shockwave therapy revenue in 2025, making it the world's largest single regional market, which is structurally favorable for any U.S.-based franchise provider in this space. Macro demand drivers are durable: the aging U.S. population is expanding the patient pool for musculoskeletal and erectile dysfunction treatments simultaneously, sports injury rates continue to rise across recreational and professional athletic demographics, and the consumer shift away from opioid-dependent pain management has created unprecedented patient willingness to explore non-invasive alternatives. Radial pressure wave devices — the modality most associated with accessible, lower-cost treatment delivery — led the technique segment with a 40.45% revenue share in 2025, favoring the clinic-based delivery model that Wavetech Therapy has standardized. The competitive landscape remains relatively fragmented, with few nationally franchised acoustic wave therapy providers operating at scale, which creates a first-mover window for brands that can execute rapid multi-unit expansion before the space consolidates.

Because Wavetech Therapy has not publicly disclosed its complete franchise financial terms through easily searchable FDD databases, prospective investors should approach the investment sizing question with the rigor the decision demands. The franchise fee, royalty rate, advertising fund contribution, total investment range, liquid capital requirement, and net worth requirement are not available in public search results as of this writing, which means any serious candidate must obtain the Franchise Disclosure Document directly from the franchisor for a complete picture of the cost of entry. What industry context can provide, however, is a useful benchmarking framework. Healthcare services franchises in the specialty clinic category — particularly those operating in non-invasive treatment niches — typically carry franchise fees ranging from $25,000 to $50,000, with total investment ranges that vary widely based on whether a location requires a de novo build-out or a conversion of existing clinical space. A single acoustic wave therapy session is priced between $500 and $1,500 per session, with treatment packages typically involving multiple sessions, suggesting a revenue-per-patient engagement that is meaningfully higher than primary care or physical therapy visits. Financing options including 14-month interest-free payment plans for patients have been noted at Wavetech Therapy locations, which reduces conversion friction and supports volume throughput. Free consultations are offered as a patient acquisition mechanism, which is a standard but effective clinical marketing practice. The absence of published franchise financial terms is a transparency gap that investors should specifically probe during the discovery process. The brand's FPI Score on PeerSense is 47, rated "Fair," which reflects the early-stage nature of the system alongside limited publicly available performance documentation. For comparison purposes, SBA eligibility and any available veteran incentive programs should be confirmed directly with the franchisor during the formal franchise application process.

The Wavetech Therapy operating model is built around delivering acoustic wave therapy sessions in a clinical outpatient setting, with patient care managed by trained practitioners using FDA-registered shockwave technology. Daily operations center on patient consultations, treatment delivery across a defined menu of conditions — including erectile dysfunction, Peyronie's disease, sports injuries, neuropathy, chronic pain, diabetic wounds, and carpal tunnel — scheduling, and ongoing patient follow-up to monitor treatment outcomes and encourage completion of multi-session protocols. The staffing model is lean by design: acoustic wave therapy does not require the same credentialing infrastructure as surgical or pharmaceutical interventions, which reduces the labor cost floor relative to many medical franchise concepts. Dr. Gabe Frank, a Medical Doctor and documented Wavetech Therapy franchisee operating out of the Wilmington, North Carolina location, serves as a real-world proof point that physician-owners are actively participating in the franchise system, suggesting the brand may attract both clinically credentialed operators and business-oriented franchisees who hire clinical staff. The technology itself — low-intensity acoustic wave generators — requires operational training to administer safely and effectively, and the company notes that its founding team consisted of experienced healthcare professionals, implying that training programs are grounded in clinical best practices rather than purely commercial protocols. Territory structure, exclusivity provisions, format options, and the specifics of corporate field support infrastructure are not publicly documented, which is an area where the FDD will provide critical clarity for any investor conducting proper due diligence. The treatment's key selling point from an operations standpoint is notable: sessions are described as pain-free with zero known side effects and zero downtime, allowing patients to resume normal activities immediately following treatment — a clinical profile that reduces no-show rates and lowers the operational complexity associated with post-procedure patient management compared to more invasive care models.

Item 19 financial performance data is not disclosed in the current Franchise Disclosure Document for Wavetech Therapy. This is a critical transparency consideration. Under Federal Trade Commission franchise regulations, franchisors are not legally required to provide financial performance representations, but when they choose not to disclose Item 19 data, prospective investors are left without a direct benchmark for evaluating potential revenue, margins, or return on investment at the unit level. Approximately half of all franchisors in the United States include some form of Item 19 disclosure, meaning Wavetech Therapy's non-disclosure places it in a common but less investor-friendly category. What public information and industry benchmarks can suggest, however, provides a useful starting framework. At a session price of $500 to $1,500 and a multi-session treatment protocol typical of acoustic wave therapy, a single patient completing a standard treatment course could represent $3,000 to $9,000 in gross revenue to the clinic. If a clinic delivers even ten completed treatment courses per month — a conservative utilization assumption for a five-day-per-week clinic — annual gross revenue would fall in the range of $360,000 to $1,080,000, depending on session pricing and treatment package structure. The shockwave therapy market's 9.13% CAGR through 2031 implies that demand-side conditions are supportive of growing patient volume over the medium term, which benefits operators who establish clinical presence early in high-demand geographies. The absence of Item 19 data means that this revenue modeling is entirely speculative without access to actual system-wide performance data, and investors should push hard during the discovery process for any voluntary financial performance disclosures, as well as direct conversations with existing franchisees like Dr. Gabe Frank whose real-world experience would be invaluable in stress-testing any pro forma assumptions. Patient reviews currently available for Wavetech Therapy clinics are broadly positive, citing noticeable improvements in ED, neuropathy, and sports injuries often within a few sessions, with some reporting long-lasting effects — anecdotal signals that are consistent with a therapy that generates genuine patient outcomes rather than placebo-driven satisfaction.

Wavetech Therapy's growth trajectory from its 2015 founding to its fifth clinic opening in Chattanooga in June 2023 reflects a deliberate, measured expansion pace rather than an aggressive unit-count push. The current documented footprint includes Greensboro NC, Raleigh NC, Knoxville TN, Birmingham AL, Chattanooga TN, and Wilmington NC — a southeastern corridor that suggests either a regional hub-and-spoke expansion strategy or an opportunistic development model driven by franchisee interest. With a current total unit count of two in the PeerSense database alongside one documented franchised unit, the brand is squarely in the early-stage franchise development phase, which carries both risk and opportunity in equal measure. The competitive moat for Wavetech Therapy rests on several structural factors: FDA-registered technology status provides a credibility signal that differentiates it from unregulated wellness competitors; the multi-condition treatment menu spanning erectile dysfunction, Peyronie's disease, sports injuries, neuropathy, chronic pain, diabetic wounds, and carpal tunnel creates a broader addressable patient pool than single-condition providers; and the non-invasive, zero-downtime treatment profile generates strong word-of-mouth referral dynamics that can be leveraged with relatively modest marketing spend. The broader shockwave therapy market is seeing accelerating technological investment, including AI-guided treatment systems, digital therapy planning platforms, and personalized treatment design tools — developments that will likely flow into franchise system updates as the technology matures. The Asia-Pacific shockwave therapy market is projected to grow at an 11.22% CAGR through 2031, indicating that global expansion is a potential long-term corporate lever, though no international operations have been announced. For investors tracking this brand, the key corporate development signals to watch include franchisee count growth, geographic expansion outside the southeastern corridor, and any leadership announcements that signal institutional investment or accelerated development commitments.

The ideal Wavetech Therapy franchisee profile skews toward candidates who sit at the intersection of healthcare familiarity and entrepreneurial ambition. The documented presence of a Medical Doctor among the franchisee base — Dr. Gabe Frank in Wilmington, NC — suggests the brand attracts clinically credentialed operators, but the franchise model's non-surgical, non-pharmaceutical nature means that medical licensure is not necessarily a prerequisite for ownership, particularly for operators who hire qualified clinical staff. Healthcare administration backgrounds, physical therapy practice ownership experience, or adjacent wellness business ownership would all represent transferable foundations for operating a Wavetech Therapy clinic. The southeastern United States represents the brand's current geographic concentration, meaning early-mover opportunities may still exist in markets across the Carolinas, Tennessee, Alabama, and adjacent states where the brand already has operational experience and potentially existing referral networks. Multi-unit development expectations are not publicly documented, but at the brand's current stage of franchise development, single-unit entry is the logical starting point, with multi-unit rights likely negotiable for candidates with relevant operational capacity. The timeline from franchise agreement execution to clinic opening will depend heavily on site selection, lease negotiation, and equipment procurement — variables that the FDD and franchisor disclosure process will clarify for qualified candidates. With a shockwave therapy market growing at 9.13% annually through 2031 and North America holding 35.30% of global revenue, the macro window for establishing franchise territory in this space is open and narrowing as awareness of the treatment modality expands.

The Wavetech Therapy franchise opportunity presents a genuinely distinctive investment thesis for the right candidate: a non-invasive, FDA-registered healthcare services franchise operating in a $1.71 billion global market growing at 9.13% annually, treating conditions — erectile dysfunction, neuropathy, chronic pain, sports injuries, diabetic wounds — that collectively affect tens of millions of Americans with limited non-surgical alternatives. The brand's early-stage development status, reflected in its FPI Score of 47 on PeerSense, is an honest signal that this is not a mature, proven system with decades of franchisee performance data — it is an emerging franchise concept in an accelerating market, where the risk-reward calculus is fundamentally different from investing in a 500-unit established brand. That distinction deserves serious weight in any investor's diligence process. The absence of Item 19 financial performance disclosure, the limited publicly available franchise cost data, and the small current unit count all underscore the importance of thorough independent research before committing capital. PeerSense provides exclusive due diligence data including SBA lending history, FPI score analysis, location maps with Google ratings, FDD financial data, and side-by-side comparison tools that allow investors to benchmark Wavetech Therapy against alternative franchise opportunities within the healthcare services and specialty clinic category. For an investment decision of this magnitude — in a space where the market fundamentals are compelling but the brand-specific track record is still being written — the quality of your pre-investment research is the single biggest variable you control. Explore the complete Wavetech Therapy franchise profile on PeerSense to access the full suite of independent franchise intelligence data.